Drug intelligence / Profile preview

Angeloxin

Development stage: Preclinical
Lead developer: Angelica Therapeutics
Modality: Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics

Overview

**Angeloxin** is a fusion toxin protein in preclinical development as an anti-cancer agent. It consists of deimmunized diphtheria toxin (DT) fused to interleukin-2 (IL-2), designed to target and kill cancer cells expressing IL-2 receptors, which are often upregulated on tumor cells and regulatory T cells in the tumor microenvironment. Developed by Angelica Therapeutics, it leverages the cytotoxic activity of DT to selectively induce cell death in targeted cancer cells while minimizing immunogenicity through deimmunization.

Other names: Her2-DIDTHer-2-DIDTHer 2-DIDT

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on Angeloxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angeloxin.

Explore the full profile